Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24644832 | 0.84 | CA1 (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL15720166 | 0.84 | CA1 (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL563401 | 0.84 | CA1 (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL24252534 | 0.84 | CA1 (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14342829 | 0.84 | CA1 (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL564154 | 0.83 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL563053 | 0.82 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL563979 | 0.82 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL562012 | 0.82 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL563696 | 0.81 | LMNA (0.49) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11231424-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200240991-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2020-07-30 | — | — | US | disclosed |
| US-20150044693-A1 | Levetiracetam Immunoassays | ARK DIAGNOSTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150044693-A1 | Levetiracetam Immunoassays | ARK DIAGNOSTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8841136-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841136-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2349335-B1 | LEVETIRACETAM IMMUNOASSAYS | ARK DIAGNOSTICS INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-8492416-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20120190047-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2012-07-26 | — | — | US | disclosed |
| US-20120190047-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2012-07-26 | — | — | US | disclosed |
| US-8034958-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UOB Pharma, S.A. (BE) | 2011-10-11 | — | — | US | disclosed |
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2010-07-08 | — | — | US | disclosed |
| WO-2010048423-A1 | LEVETIRACETAM IMMUNOASSAYS | ARK DIAGNOSTICS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-7692028-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-04-06 | — | — | US | disclosed |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20050171187-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | DIFFERDING EDMOND (BE) | 2005-08-04 | — | — | US | disclosed |
| US-6911461-B2 | For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse | UCB, S.A. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-6806287-B2 | NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE | UCB, S.A. (BE) | 2004-10-19 | — | — | US | disclosed |
| US-6784197-B2 | SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS | UCB S.A. (BE) | 2004-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171187-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | LMNA 3694/4885CA12 4426/4885CA1 2098/4885 |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | LMNA 3694/4885CA12 4426/4885CA1 2098/4885 |
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | LMNA 3694/4885CA12 4426/4885CA1 2098/4885 |
| US-20200240991-A1 | Levetiracetam Immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-20120190047-A1 | Levetiracetam Immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-11231424-B2 | Levetiracetam immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.